Zymeworks Inc. (ZYME.TO)
| Previous Close | 32.57 |
| Open | 33.05 |
| Bid | 33.04 x 0 |
| Ask | 33.14 x 0 |
| Day's Range | 32.77 - 33.53 |
| 52 Week Range | 32.77 - 33.53 |
| Volume | |
| Avg. Volume | 5,400 |
| Market Cap | 1.3B |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.55 |
| Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
VANCOUVER, British Columbia & SEATTLE, June 27, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer. Dr. Moore brings more than 25 years of US-based experience in biologics drug discovery and development in biotechnology res
- Business Wire
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
VANCOUVER, British Columbia & SEATTLE, June 10, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the "Board") has adopted a limited-duration shareholder rights plan (the "Rights Plan"). The Board adopted the Rights Plan in response to the unsolicited, non-binding proposal by All Blue Falcons FZE ("All Blue") to acquire Zymeworks and All Blue’s continued share accu
- Business Wire
Zymeworks Announces Participation in Upcoming Investor Conference
VANCOUVER, British Columbia & SEATTLE, May 27, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
